Neurogene Inc.
NGNE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404644
No open-market purchases or sales by Neurogene Inc. insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $544.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $519.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +17 vs. previous quarter
- 111
- 13F valueReported value at the end of Q2 2026
- $544.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- −100.0% year over year
- Net income, FY2025
- -$90.4M
- No comparable prior period
- Free cash flow, FY2025
- -$78.4M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.69M
- Shares sold short
- Change
- +592.4K
- +11.6% vs. previous
- Days to cover
- 16.95
- At average daily volume
Superinvestors holding NGNE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding NGNE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Neurogene Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)9:08 PM ET | Jul 6-7 | 1 day | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $36.12 | −$173.4K | −5.4%84.0K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)6:42 PM ET | Jul 1-2 | 1 day | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $34.71 | −$166.6K | −5.1%88.8K after | 3 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Cvijic Christine MikailPresident and CFO | SSale | −9.60K | $31.26 | −$300.0K | −9.3%93.6K after | 2 lots10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Jordan JulieChief Medical Officer | SSale | −828 | $21.89 | −$18.1K | −6.2%12.5K after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | McMinn RachelChief Executive Officer | SSale | −3.35K | $22.07 | −$74.0K | −0.2%1.34M after | 10b5-1 |
| Mar 30, 2026 (view filing) | Mar 26 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −2.56K | $21.62 | −$55.3K | −2.4%103.2K after | 10b5-1 |
| Mar 17, 2026 (view filing) | Mar 13 | 4 days | Cobb StuartChief Scientific Officer | SSale | −6.80K | $20.81 | −$141.4K | −18.2%30.5K after | 3 lots10b5-1 |
| Mar 17, 2026 (view filing) | Mar 13 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.04K | $20.81 | −$84.2K | −3.7%105.8K after | 3 lots10b5-1 |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Cvijic Christine MikailPresident and CFO | SSale | −4.80K | $25.11 | −$120.5K | −4.2%109.8K after | 10b5-1 |
| May 15, 2025 (view filing) | May 14 | 1 day | Cobb StuartChief Scientific Officer | SSale | −6.80K | $15.15 | −$103.0K | −24.6%20.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 111 holdersThe largest institutional positions in Neurogene Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 1,717,127 | $54.0M | 4.44% | 00.0% | Unchanged |
| Casdin Capital, LLC | 1,545,361 | $48.6M | 2.43% | +125,000+8.8% | Added |
| Redmile Group, LLC | 1,412,199 | $44.4M | 2.98% | −47,400−3.2% | Reduced |
| RTW Investments, LP | 1,362,456 | $42.8M | 0.37% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 1,271,342 | $40.0M | 1.98% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,057,983 | $33.3M | 0.00% | +52,913+5.3% | Added |
| Baker Bros. Advisors LP | 991,691 | $31.2M | 0.16% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 818,706 | $25.7M | 0.05% | +100,317+14.0% | Added |
| Trails Edge Capital Partners, LP | 714,885 | $22.5M | 3.57% | −67,902−8.7% | Reduced |
| Toronto Dominion Bank | 681,337 | $21.4M | 0.04% | 00.0% | Unchanged |
Holders of 5% or more of NGNE
See all 9 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Neurogene Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Prudential Financial Inc | 13G | 11.20%2.23M shares | New | Oct 7, 20261 filing | Oct 7, 2026 | SEC |
| Jennison Associates LLC | 13G | 11.10%2.23M shares | New | Oct 6, 20261 filing | Oct 6, 2026 | SEC |
| RTW Investments, LP | 13G/A | 9.99%1.50M shares | – | Nov 14, 20242 filings | Feb 14, 2025 | SEC |
| Redmile Group, LLC | 13G/A | 9.90%1.57M shares | 0.00 ppfrom 9.90% | Feb 16, 20219 filings | Aug 14, 2026 | SEC |
| EcoR1 Capital, LLC | 13G/A | 9.90%1.44M shares | – | Feb 16, 20214 filings | Nov 14, 2025 | SEC |